Navigation Links
Low adherence to biopsy guidelines affects celiac disease diagnosis in the United States
Date:7/7/2011

NEW YORK, NY (July 6, 2011) - A new study has found that most patients undergoing biopsy of the small intestine do not have the recommended number of samples to diagnose celiac disease. The study, published in the July 2011 issue of Gastrointestinal Endoscopy, analyzed a national database of biopsy specimens maintained by Caris Life Sciences (Irving, TX). More than 100,000 patients had a biopsy of the small intestine, but only 35 percent of them had at least four samples taken, the number recommended by professional guidelines.

Celiac disease is common, affecting approximately 1 percent of the population in the United States. However, the vast majority of patients with celiac disease in the United States have not been diagnosed. Many of these patients seek health care for symptoms including diarrhea, weight loss, or fatigue due to anemia. The diagnosis of celiac disease is made by biopsy of the small intestine, but factors related to the performance of biopsy may contribute to the under-diagnosis of celiac disease in the United States.

"Celiac disease can affect the small intestine in a patchy distribution, and so just one or two biopsy samples could potentially miss the evidence of the disease," said lead author Benjamin Lebwohl, MD, MS, a gastroenterologist at the Celiac Disease Center at Columbia University Medical Center, in New York. Dr. Lebwohl and co-authors aimed to measure the practice of small intestinal biopsy in the United States. The Caris pathology database consists of specimens submitted by gastroenterologists from 43 states as well as Puerto Rico and the District of Columbia. The team also compared the diagnosis rate among patients who had at least four specimens submitted, in accordance with guidelines.

The investigators identified 132,352 individuals who underwent biopsy between 2006 and 2009, for a variety of medical indications, including diarrhea, abdominal pain, esophageal reflux, and anemia. Only 35 percent of this group had at least four specimens submitted, and the most common number of specimens submitted was two. But adhering to the recommendation of submitting at least four specimens more than doubled the diagnosis rate of celiac disease.

Even when physicians indicated that they were suspicious of celiac disease (e.g., when patients had positive celiac disease blood tests), fewer than 40 percent of patients had at least four specimens submitted; the diagnosis was increased sevenfold when the guidelines were followed.

"The process of increasing the number of specimens from two to four takes approximately one extra minute during endoscopy," said Dr. Lebwohl. Given the high incremental yield of submitting at least four specimens, taking this extra minute appears to be justified.

"In this study we identified just one of the factors contributing to the high rate of under-diagnosis of celiac disease in the United States. We plan on studying other physician-related factors that may also be operative," said Dr. Peter Green, Director of the Celiac Center Columbia University Medical Center, who was also an author on the paper.


'/>"/>

Contact: Cynthai Beckman
cb2280@columbia.edu
646-812-1212
Columbia University Medical Center
Source:Eurekalert

Related biology news :

1. Link between fracture prevention and treatment adherence not fully understood by patients
2. Novel technique changes lymph node biopsy, reduces radiaiton exposure
3. Novel technique changes lymph node biopsy, reduces radiation exposure
4. Montana State grads work helps diagnose skin cancer without a biopsy
5. Multicolor quantum dots aid in cancer biopsy diagnosis
6. Microfluidics-imaging platform detects cancer growth signaling in minute biopsy samples
7. Guidelines urge physical activity during pregnancy
8. The International Society for Stem Cell Research releases new guidelines
9. Publication sets guidelines across cancer therapies: Ensuring the best in patient management
10. Coral Disease Handbook: Guidelines for Assessment, Monitoring and Management
11. First comprehensive guidelines for managing medullary thyroid carcinoma published in Thyroid journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... Jan. 5, 2017  Delta ID Inc., a leader ... technology for automotive at CES® 2017. Delta ID has ... to demonstrate the use of iris scanning as a ... the driver in a car, and as a way ... experience. Delta ID and Gentex will demonstrate ...
(Date:12/22/2016)... MOUNTAIN VIEW, Calif. , Dec. 20, 2016  As ... all levels, 23andMe, the leading personal genetics company, recently released ... Only Me . The book focuses on the topics ... the Next Generation Science Standards (NGSS) taught in elementary school ... the second in a series by illustrator Ariana Killoran ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... BETHESDA, Md. , Jan. 18, 2017  Northwest ... company developing DCVax® personalized immune therapies for operable and ... Marnix Bosch , Chief Technical Officer of NW Bio, ... Thursday, January 19, 2017, at the Hyatt Regency Hotel ... Dr. Bosch will chair the session entitled "New Therapeutic ...
(Date:1/19/2017)... LAKES, N.J. , Jan. 18, 2017 BD (Becton, ... technology company, announced today that it will host a live webcast ... at 1 p.m. (ET). The webcast can be ... be available for replay through Tuesday, January 31, 2017. ... About BD BD ...
(Date:1/18/2017)... According to a new market research report "In situ Hybridization Market by ... (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published ... from USD 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017 ... applying mechanistic modeling to drug research and development, ... PhD, Co-Founder, President, and CEO of Applied BioMath, ... for Informatics and Modeling (BAGIM) Meeting on Thursday ... Cambridge , MA.   Dr. Burke,s ...
Breaking Biology Technology: